focus -WSS

focus

author：explore 2025-08-26 10:55:48 - browse：54847

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： Manchin plays down potential 3rd

WSS

UK homeowners get some respite as inflation falls by more than anticipated to a 15

Apple is now the first public company to be valued at $3 trillion

Bright Health sells Medicare Advantage business to Molina

ChatGPT in medicine: STAT answers readers' burning questions

Twill hunts for pharma partner to market its depression app

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

knowledge

focus

leisure time

Guidelines to prevent youth baseball injuries need more muscle

Cancer drug shortages should be causing more outrage

Heart attack and stroke risk calculators need revising

DeSantis says Trump could've 'come out more forcefully' during Jan. 6

Sports medicine is finally prioritizing gender equality

BridgeBio heart drug succeeds in pivotal study

George Santos makes 1st court appearance after pleading not guilty to 13 counts

A strong 6.5

Bright Health sells Medicare Advantage business to Molina

Guidelines to prevent youth baseball injuries need more muscle

focus

What does generative AI mean for health care? We asked experts

A Theranos scientist

Robert Kennedy Jr.'s presidential campaign attracts GOP

Apple is now the first public company to be valued at $3 trillion

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

Medicare proposal to cover medical devices draws a mixed reaction

hotspot

hotspot

focus

explore